中华肿瘤杂志
中華腫瘤雜誌
중화종류잡지
CHINESE JOURNAL OF ONCOLOGY
2013年
4期
301-304
,共4页
时圣彬%马廷行%唐晓勇%李春华
時聖彬%馬廷行%唐曉勇%李春華
시골빈%마정행%당효용%리춘화
胰腺肿瘤%二线治疗%卡培他滨%沙利度胺
胰腺腫瘤%二線治療%卡培他濱%沙利度胺
이선종류%이선치료%잡배타빈%사리도알
Pancreatic neoplasms%Second line treatment%Capecitabine%Thalidomide
目的 研究卡培他滨联合沙利度胺在晚期胰腺癌二线治疗中的临床疗效,探讨沙利度胺在胰腺癌治疗中的疗效和安全性.方法 采用随机数字法将含吉西他滨一线治疗的61例晚期胰腺癌患者随机分为两组,分别给予单药卡培他滨(单药组)以及卡培他滨联合沙利度胺(联合组)治疗,评价两组患者的疗效和毒副反应.结果 单药组和联合组患者的的无进展生存时间(PFS)分别为2.8个月(95％ CI为2.4 ～3.2个月)和3.1个月(95％ CI为2.6 ～3.6个月),差异有统计学意义(P＜0.05)；总生存时间(OS)分别为6.1个月(95％ CI为5.3 ～6.9)和6.3个月(95％ CI为5.2～7.4,P＞0.05).31例单药组患者部分缓解(PR)1例,疾病稳定(SD)10例,疾病进展(PD)20例；30例联合组患者PR 2例,SD 11例,PD 17例.单药组和联合组患者的疾病控制率分别为35.5％和43.3％,差异无统计学意义(P =0.272).两组患者的毒副反应主要为Ⅲ～Ⅳ度腹泻.结论 卡培他滨联合沙利度胺能够延长晚期胰腺癌患者的PFS,且毒副反应耐受性良好,是一种安全有效的方案.
目的 研究卡培他濱聯閤沙利度胺在晚期胰腺癌二線治療中的臨床療效,探討沙利度胺在胰腺癌治療中的療效和安全性.方法 採用隨機數字法將含吉西他濱一線治療的61例晚期胰腺癌患者隨機分為兩組,分彆給予單藥卡培他濱(單藥組)以及卡培他濱聯閤沙利度胺(聯閤組)治療,評價兩組患者的療效和毒副反應.結果 單藥組和聯閤組患者的的無進展生存時間(PFS)分彆為2.8箇月(95％ CI為2.4 ～3.2箇月)和3.1箇月(95％ CI為2.6 ～3.6箇月),差異有統計學意義(P＜0.05)；總生存時間(OS)分彆為6.1箇月(95％ CI為5.3 ～6.9)和6.3箇月(95％ CI為5.2～7.4,P＞0.05).31例單藥組患者部分緩解(PR)1例,疾病穩定(SD)10例,疾病進展(PD)20例；30例聯閤組患者PR 2例,SD 11例,PD 17例.單藥組和聯閤組患者的疾病控製率分彆為35.5％和43.3％,差異無統計學意義(P =0.272).兩組患者的毒副反應主要為Ⅲ～Ⅳ度腹瀉.結論 卡培他濱聯閤沙利度胺能夠延長晚期胰腺癌患者的PFS,且毒副反應耐受性良好,是一種安全有效的方案.
목적 연구잡배타빈연합사리도알재만기이선암이선치료중적림상료효,탐토사리도알재이선암치료중적료효화안전성.방법 채용수궤수자법장함길서타빈일선치료적61례만기이선암환자수궤분위량조,분별급여단약잡배타빈(단약조)이급잡배타빈연합사리도알(연합조)치료,평개량조환자적료효화독부반응.결과 단약조화연합조환자적적무진전생존시간(PFS)분별위2.8개월(95％ CI위2.4 ～3.2개월)화3.1개월(95％ CI위2.6 ～3.6개월),차이유통계학의의(P＜0.05)；총생존시간(OS)분별위6.1개월(95％ CI위5.3 ～6.9)화6.3개월(95％ CI위5.2～7.4,P＞0.05).31례단약조환자부분완해(PR)1례,질병은정(SD)10례,질병진전(PD)20례；30례연합조환자PR 2례,SD 11례,PD 17례.단약조화연합조환자적질병공제솔분별위35.5％화43.3％,차이무통계학의의(P =0.272).량조환자적독부반응주요위Ⅲ～Ⅳ도복사.결론 잡배타빈연합사리도알능구연장만기이선암환자적PFS,차독부반응내수성량호,시일충안전유효적방안.
Objective This study investigates the efficacy and tolerability of capecitabine plus thalidomide in patients with advanced pancreatic cancer who previously underwent gemcitabine-based therapy.Methods Sixty-one patients with unresectable or metastatic PC who had progressed on single-agent Gem or a Gem-containing regimen were enrolled.The patients were randomly divided into two groups.One group (31 patients) was treated with capecitabine alone,and another group was treated with capecitabine plus thalidomide.Capecitabine was administered orally twice a day at a dose of 1,250 mg/m2 for 14-day followed by 7-day rest and oral thalidomide 100 mg was given daily without interruption until disease progression or occurrence of unacceptable toxicity.Results The PFS was 2.8 months (95％ CI 2.4-3.2) vs.3.1 months (95％ CI 2.6-3.6,P＜0.05) and the OSwas6.1 months (95％ CI5.3-6.9) vs.6.3 months (95％ CI 5.2-7.4,P =0.426).In the capecitabine alone group,one patient experienced a partial response (PR),10 patients showed stable disease (SD) and 20 patients had progressive disease (PD).The another group,two patients experienced a partial response (PR),11 patients SD,and 17 patients PD.The disease control rates were 35.5％ and 43.3％,respectively.The major adverse reaction in the two groups was grade 3 diarrhea.Conclusion Capecitabine plus thalidomide regimen is marginally effective and well tolerated in the second-line setting in patients with gemcitabine-refractory advanced pancreatic cancer.
